Литература
1. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016; 23(4):209-213. doi: 10.1080/13506129.2016.1257986.
2. Диагностика и лечение АА и AL амилоидоза. Национальные клинические рекомендации [Электронный ресурс]. Научное общество нефрологов России. 2014. http://http://nonr. ru/?page_id=3178/.
3. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood.2009; 114(24): 4957-4959. doi: 10.1182/blood-2009-07-230722.6.
4. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013; 161: 525-532. doi: 10.1111/bjh.12286.
5. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies. A Scientific Statement From the American Heart Association. Circulation. 2016; 134(23):579-646. doi: 10.1161/CIR.0000000000000455.
6. Nienhuis H, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis 2016; 2:10-19. doi: 10.1159/000444206.
7. Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K: Incidence and survival in nonhereditary amyloidosis in Sweden. BMC Public Health. 2012; 12: 974. doi: 10.1186/1471-2458-12-974
8. Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med. 1986; 29:376-385.
9. Röcken C, Eriksson M. Amyloid and amyloidosis. Pathologe. 2009 ; 30(3):182-92. doi: 10.1007/s00292-009-1128-1.
10. Щаднева С.И., Пархоменко Ю.В., Белозерцева Л.В., Костроченко Л.М. Маски амилоидоза. Современные проблемы ревматологии. 2012; 4(4):32-42.
11. Kumar V., Abbas A., Aster D., Fausto N. Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Saunders Elsevier; 2010:464-474 [
12. Pettersson T, Konttinen YT. Amyloidosis-recent developments. Semin Arthritis Rheu. 2010, 39: 356–368.
13. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M: Patterns of survival in multiple myeloma: a populationbased study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007, 25: 1993–1999.
14. Сергиенко В.Б., Терещенко С.Н., Аншелес А.А., Жиров И.В., Сафиуллина А.А. Радионуклидные методы в диагностике амилоидоза сердца. Рациональная фармакотерапия в кардиологии. 2018;14(1):94-100. doi: 10.20996/1819-6446- 2018-14-1-94-100.
15. Falk R.H., Rubinow A., Cohen A.S. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984; 3(1):107-13. doi: 10.1016/ s0735-1097(84)80436-2.
16. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95: 535–537. doi: 10.1016/j.amjcard.2004.10.028.
17. Ахунова C.А., Барсуковская Т.А., Рафиков А.Ю., Сайфуллина Г.Б. Роль эхокардиографии в диагностике амилоидоза сердца. Практическая медицина. 2018, 1 (112):37-42.
18. Благова О.В, Недоступ А.В., Седов В.П., Коган Е.А., Паша С.П., Гагарина Н.В. и др. Клинические маски амилоидоза с поражением сердца: особенности диагностики на современном этапе. Российский Кардиологический Журнал.2017;2(142):68-79.
19. Zhao L., Tian Z., Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord.2016;16: 129. doi: 10.1186/s12872-016-0311-6.
20. Kumar S1, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements // J ClinOncol. 2012; 30(9): 989–995. doi: 10.1200/JCO.2011.38.5724.
21. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med. 2003, 349: 583-596. doi: 10.1056/NEJMra023144
22. Kyle RA, Rajkumar SV: Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007, 20: 637-664. doi: 10.1016/j. beha.2007.08.001.
23. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA et al: Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011, 90: 101-106. doi: 10.1007/ s00277-010-1028-8.
24. Мясников Р.П., Андреенко Е.Ю., Кушунина Д.В., Максимова О.Б., Береговская С.А. , Мершина Е.А. и др. Амилоидоз сердца: современные аспекты диагностики и лечения. Клиническая и экспериментальная хирургия. 2014; 4: 72-82.
25. Kyle, RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine.1975; 54(4): 271-299.
26. Сomenzo, R. L. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007; 5(2):179-186.
27. Kyle, R. A. Amyloidosis: a convoluted story. British journal of haematology. 2001; 114(3): 529-538.
28. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006; 42: 1671-1683. doi: 10.1016/j.ejca.2006.01.065.
29. Milani P, Palladini G, Merlini G. New concepts in the treatment and diagnosis of amyloidosis, Expert Review of Hematology.2018; 11(2):117-127, doi: 10.1080/17474086.2018.1424534.
30. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N. Engl. J. Med. 2008; 358 (6):615-24. doi: 10.1056/NEJMcp074189.
31. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997; 80(9): 1242-1245.
32. Kyle, RA, Gertz, MA. Primary systemic amyloidosis, clinical and laboratory features in 474 cases. Semin Hematol. 1995; 32: 45–59.
33. Cantwell RV, Aviles RJ, Bjornsson J, Wright RS, Freeman WK, Oh JK et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clinical Cardiology. Clin Cardiol. 2002; 25(1): 33-37.
34. Егоров И.В. Редкие формы миеломной болезни. Клиническая Медицина. 2004; 82( 2):50-55